

Infusion Rate Overview

INDICATIONS

GAMMAGARD LIQUID [Immune Globulin Infusion (Human)] 10% is indicated as a replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older, as a maintenance therapy to improve muscle strength and disability in adult patients with Multifocal Motor Neuropathy (MMN), and as a therapy to improve neuromuscular disability and impairment in adult patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).

LIMITATIONS OF USE (CIDP): GAMMAGARD LIQUID has not been studied in immunoglobulin-naïve patients with CIDP. GAMMAGARD LIQUID maintenance therapy in CIDP has not been studied for periods longer than 6 months. After responding during an initial treatment period, not all patients require indefinite maintenance therapy with GAMMAGARD LIQUID in order to remain free of CIDP symptoms. Individualize the duration of any treatment beyond 6 months based upon the patient's response and demonstrated need for continued therapy.

GAMMAGARD LIQUID for PI is for intravenous or subcutaneous use.

GAMMAGARD LIQUID for MMN and CIDP is for intravenous use only.

IMPORTANT SAFETY INFORMATION

WARNING: THROMBOSIS, RENAL DYSFUNCTION, AND ACUTE RENAL FAILURE

- Thrombosis may occur with immune globulin (IG) products, including GAMMAGARD LIQUID. Risk factors may include advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors.
- Renal dysfunction, acute renal failure, osmotic nephrosis, and death may occur in predisposed patients with immune globulin intravenous (IGIV) products. Patients predisposed to renal dysfunction include those with any degree of pre-existing renal insufficiency, diabetes mellitus, age greater than 65, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs. Renal dysfunction and acute renal failure occur more commonly in patients receiving IGIV products containing sucrose. GAMMAGARD LIQUID does not contain sucrose.
- For patients at risk of thrombosis, administer GAMMAGARD LIQUID at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.

Please see detailed infusion rate tables and example calculations in the below pages for your patients with approved indications.

Rate increases shown here are for educational purposes only and should not be interpreted as clinical guidance. Healthcare professionals are ultimately responsible to determine the appropriate dose for each patient based on patient examination, characteristics, and medical judgment.



**For Medical Information, please
call 1-877-TAKEDA-7 (1-877-825-3327)
or email medinfous@takeda.com.**

Please see additional Important Safety Information throughout, including Boxed Warnings for Thrombosis, Renal Dysfunction, and Acute Renal Failure, and click for [Full Prescribing Information](#).

For patients with Primary Immunodeficiency (PI)¹

GAMMAGARD LIQUID
[Immune Globulin Infusion (Human)] 10%

INFUSION RATE (mL/kg/hr)								DOSING	
mL/kg/hr	Initial infusion rate ¹		Maintenance infusion rate				Maximum infusion rate ¹	PI total dose: 300 to 600 mg/kg (0.3 to 0.6 g/kg) every 3 to 4 weeks based on clinical response ¹	
	0.5	1.0	2.0 ^a	3.0	4.0	5.0			
Time ^b								Calculated dosing for PI	
Body weight	0-30 min	30 min-1 hr	1 hr-1 hr 30 min	1 hr 30 min-2 hrs	2 hrs-2 hrs 30 min	2 hrs 30 min, or end of infusion for PI			
lb	kg	Calculated infusion rates (mL/hr) ^c						Minimum (g)	Maximum (g)
22	10	5	10	20	30	40	50	3	6
33	15	7.5	15	30	45	60	75	4.5	9
44	20	10	20	40	60	80	100	6	12
55	25	12.5	25	50	75	100	125	7.5	15
66	30	15	30	60	90	120	150	9	18
77	35	17.5	35	70	105	140	175	10.5	21
88	40	20	40	80	120	160	200	12	24
99	45	22.5	45	90	135	180	225	13.5	27
110	50	25	50	100	150	200	250	15	30
121	55	27.5	55	110	165	220	275	16.5	33
132	60	30	60	120	180	240	300	18	36
143	65	32.5	65	130	195	260	325	19.5	39
154	70	35	70	140	210	280	350	21	42
165	75	37.5	75	150	225	300	375	22.5	45
176	80	40	80	160	240	320	400	24	48
187	85	42.5	85	170	255	340	425	25.5	51
198	90	45	90	180	270	360	450	27	54
209	95	47.5	95	190	285	380	475	28.5	57
220	100	50	100	200	300	400	500	30	60
231	105	52.5	105	210	315	420	525	31.5	63
243	110	55	110	220	330	440	550	33	66
254	115	57.5	115	230	345	460	575	34.5	69
265	120	60	120	240	360	480	600	36	72

^aFor patients over 65 years of age or judged to be at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable. In such cases, the maximal rate should be less than 3.3 mg/kg/min (<2 mL/kg/hr); consider discontinuation of administration if renal function deteriorates.

^bInfusion rates presented are examples. Infusion increments, including time, may vary.

^cInfusion rates (mL/hr) were calculated as follows: mL/kg/hr X body weight (kg).

Example

A 72-kg patient with PI is prescribed 40 grams (400 mL) of GAMMAGARD LIQUID 10% (0.1 g/mL) IV every 4 weeks. The starting infusion rate is 0.5 mL/kg/hr x 72 kg = 36 mL/hr. After 30 minutes the patient has tolerated the initial rate and received 1.8 grams of IG. The rate is increased to 1.0 mL/kg/hr x 72 kg = 72 mL/hr. The rate is gradually increased every 30 minutes based on tolerability, up to a max rate of 5 mL/kg/hr x 72 kg = 360 mL/hr, until the complete dose of IG has been administered.

IMPORTANT SAFETY INFORMATION (continued)

CONTRAINDICATIONS

- History of anaphylactic or severe systemic hypersensitivity reactions to human IG.
- IgA-deficient patients with antibodies to IgA and a history of hypersensitivity to human IG. Anaphylaxis has been reported with intravenous (IV) use of GAMMAGARD LIQUID.

Please see additional Important Safety Information throughout, including **Boxed Warnings for Thrombosis, Renal Dysfunction, and Acute Renal Failure**, and click for [Full Prescribing Information](#).

For patients with Multifocal Motor Neuropathy (MMN)¹

GAMMAGARD LIQUID
[Immune Globulin Infusion (Human)] 10%

INFUSION RATE (mL/kg/hr)				DOSING	
mL/kg/hr		Initial infusion rate ¹	Maximum infusion rate ¹	MMN total dose: 500 to 2400 mg/kg (0.5 to 2.4 g/kg) per month based on clinical response ¹	
		0.5 ^a	5.4		
Body weight		If initial infusion rate is well tolerated, consider increase to a maximum of 5.4 mL/kg/hr (9 mg/kg/min)		Calculated dosing for MMN	
lb	kg	Calculated infusion rates (mL/hr) ^b		Minimum (g)	Maximum (g)
22	10	5	54	5	24
33	15	7.5	81	7.5	36
44	20	10	108	10	48
55	25	12.5	135	12.5	60
66	30	15	162	15	72
77	35	17.5	189	17.5	84
88	40	20	216	20	96
99	45	22.5	243	22.5	108
110	50	25	270	25	120
121	55	27.5	297	27.5	132
132	60	30	324	30	144
143	65	32.5	351	32.5	156
154	70	35	378	35	168
165	75	37.5	405	37.5	180
176	80	40	432	40	192
187	85	42.5	459	42.5	204
198	90	45	486	45	216
209	95	47.5	513	47.5	228
220	100	50	540	50	240
231	105	52.5	567	52.5	252
243	110	55	594	55	264
254	115	57.5	621	57.5	276
265	120	60	648	60	288

^aFor patients over 65 years of age or judged to be at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable. In such cases, the maximal rate should be less than 3.3 mg/kg/min (<2 mL/kg/hr); consider discontinuation of administration if renal function deteriorates.

^bInfusion rates (mL/hr) were calculated as follows: mL/kg/hr X body weight (kg).

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS

Hypersensitivity: Severe hypersensitivity reactions may occur, even in patients who have tolerated previous treatment with human Ig. If a hypersensitivity reaction occurs, discontinue infusion immediately and institute appropriate treatment. IgA-deficient patients with antibodies to IgA are at greater risk of developing potentially severe hypersensitivity reactions, including anaphylaxis.

Please see additional Important Safety Information throughout, including **Boxed Warnings for Thrombosis, Renal Dysfunction, and Acute Renal Failure**, and click for [Full Prescribing Information](#).

For patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)¹

GAMMAGARD LIQUID
[Immune Globulin Infusion (Human)] 10%

INFUSION RATE (mL/kg/hr)				DOSING	
mL/kg/hr		Initial infusion rate ¹	Maximum infusion rate ¹	CIDP total induction dose: 2000 mg/kg (2 g/kg) in divided doses over 2 to 5 consecutive days, followed by maintenance infusions. Maintenance dose is 1000 mg/kg (1 g/kg) in divided doses over 1 to 4 consecutive days, every 3 weeks.	
		0.5 ^a	5.4		
Body weight		If initial infusion rate is well tolerated, consider increase to a maximum of 5.4 mL/kg/hr (9 mg/kg/min)		Calculated dosing for CIDP GAMMAGARD LIQUID maintenance therapy in CIDP has not been studied for periods longer than 6 months	
lb	kg	Calculated infusion rates (mL/hr) ^b		Minimum (g)	Maximum (g)
22	10	5	54	5	24
33	15	7.5	81	7.5	36
44	20	10	108	10	48
55	25	12.5	135	12.5	60
66	30	15	162	15	72
77	35	17.5	189	17.5	84
88	40	20	216	20	96
99	45	22.5	243	22.5	108
110	50	25	270	25	120
121	55	27.5	297	27.5	132
132	60	30	324	30	144
143	65	32.5	351	32.5	156
154	70	35	378	35	168
165	75	37.5	405	37.5	180
176	80	40	432	40	192
187	85	42.5	459	42.5	204
198	90	45	486	45	216
209	95	47.5	513	47.5	228
220	100	50	540	50	240
231	105	52.5	567	52.5	252
243	110	55	594	55	264
254	115	57.5	621	57.5	276
265	120	60	648	60	288

^aFor patients over 65 years of age or judged to be at risk for renal dysfunction or thrombotic events, administer GAMMAGARD LIQUID at the minimum infusion rate practicable. In such cases, the maximal rate should be less than 3.3 mg/kg/min (<2 mL/kg/hr); consider discontinuation of administration if renal function deteriorates.

^bInfusion rates (mL/hr) were calculated as follows: mL/kg/hr X body weight (kg).

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS

Renal Dysfunction/Failure: Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis, and death may occur with IV use of IG products, especially those containing sucrose. Acute renal dysfunction/failure has been reported in association with infusions of GAMMAGARD LIQUID. Ensure patients are not volume depleted prior to infusion. In patients at risk due to pre-existing renal insufficiency or predisposition to acute renal failure, assess renal function before initiation and throughout treatment, and use the minimum infusion rate practicable for IV administration. If renal function deteriorates, consider discontinuation.

Please see additional Important Safety Information throughout, including **Boxed Warnings for Thrombosis, Renal Dysfunction, and Acute Renal Failure**, and click for [Full Prescribing Information](#).

IMPORTANT SAFETY INFORMATION (continued)

WARNINGS AND PRECAUTIONS (continued)

Hyperproteinemia, increased serum viscosity, and hyponatremia may occur. It is critical to distinguish true hyponatremia from a pseudohyponatremia because certain treatments may lead to volume depletion, a further increase in serum viscosity, and a predisposition to thromboembolic events.

Thrombosis: May occur following treatment with IG products and in the absence of known risk factors. In patients at risk, administer at the minimum dose and infusion rate practicable. Ensure adequate hydration before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity.

Aseptic Meningitis Syndrome: Has been reported with use of IG and may occur more frequently in females. Conduct a thorough neurological exam on patients exhibiting signs and symptoms, to rule out other causes of meningitis. Discontinuing IG treatment has resulted in remission within several days without sequelae.

Hemolysis: GAMMAGARD LIQUID contains blood group antibodies, which may cause a positive direct antiglobulin reaction and hemolysis. Monitor patients for signs and symptoms of hemolysis and delayed hemolytic anemia and, if present, perform appropriate confirmatory lab testing.

Transfusion-Related Acute Lung Injury: Non-cardiogenic pulmonary edema has been reported with IV-administered IG, including GAMMAGARD LIQUID. Monitor patients for pulmonary adverse reactions. If suspected, perform appropriate tests for presence of anti-neutrophil and anti-HLA antibodies in both product and patient serum. May be managed using oxygen therapy with adequate ventilatory support.

Transmittable Infectious Agents: Because GAMMAGARD LIQUID is made from human plasma, it may carry a risk of transmitting infectious agents (e.g., viruses, other pathogens). No confirmed cases of viral transmission or variant Creutzfeldt-Jakob disease (vCJD) have been associated with GAMMAGARD LIQUID.

Interference with Lab Tests: False positive serological test results and certain assay readings, with the potential for misleading interpretation, may occur as the result of passively transferred antibodies.

ADVERSE REACTIONS

The serious adverse reactions observed in clinical studies in PI was aseptic meningitis, and in MMN were pulmonary embolism and blurred vision.

The most common adverse reactions observed in $\geq 5\%$ of patients were:

IV administration for PI: Headache, fatigue, pyrexia, nausea, chills, rigors, pain in extremity, diarrhea, migraine, dizziness, vomiting, cough, urticaria, asthma, pharyngolaryngeal pain, rash, arthralgia, myalgia, oedema peripheral, pruritus, and cardiac murmur.

Subcutaneous administration for PI: Infusion site (local) event (rash, erythema, edema, hemorrhage, and irritation), headache, fatigue, heart rate increased, pyrexia, abdominal pain upper, nausea, vomiting, asthma, blood pressure systolic increased, diarrhea, ear pain, aphthous stomatitis, migraine, oropharyngeal pain, and pain in extremity.

IV administration for MMN: Headache, chest discomfort, muscle spasms, muscular weakness, nausea, oropharyngeal pain, and pain in extremity.

IV administration for CIDP: Headache, pyrexia, anemia, leukopenia, neutropenia, illness, blood creatinine increased, dizziness, migraine, somnolence, tremor, nasal dryness, abdominal pain upper, vomiting, chills, nasopharyngitis, and pain in extremity.

DRUG INTERACTIONS

Passive transfer of antibodies may transiently interfere with immune responses to live attenuated virus vaccines (e.g., measles, mumps, rubella, and varicella).

Please see additional Important Safety Information throughout, including Boxed Warnings for Thrombosis, Renal Dysfunction, and Acute Renal Failure, and click for [Full Prescribing Information](#).

Reference: 1. GAMMAGARD LIQUID. Prescribing information. Takeda Pharmaceuticals U.S.A., Inc.; 2024.